Noxopharm Limited
Noxopharm Limited, a biotech company, engages in the discovering and developing treatments for cancer and inflammation, and mRNA vaccines in Australia. It develops Sofra, a platform that focuses on the development of immunomodulators for mRNA vaccines and mRNA therapeutics, as well as for the treatment of autoimmune diseases; and Chroma technology platform to develop CRO-67 dual-cell therapy drug… Read more
Noxopharm Limited (NOXOF) - Total Assets
Latest total assets as of June 2024: $6.78 Million USD
Based on the latest financial reports, Noxopharm Limited (NOXOF) holds total assets worth $6.78 Million USD as of June 2024.
Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments.
Noxopharm Limited - Total Assets Trend (2016–2024)
This chart illustrates how Noxopharm Limited’s total assets have evolved over time, based on quarterly financial data. Explore and compare other companies by total assets.
Noxopharm Limited - Asset Composition Analysis
Current Asset Composition (June 2024)
Noxopharm Limited's total assets of $6.78 Million consist of 70.3% current assets and 29.7% non-current assets.
| Asset Category | Amount (USD) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 34.2% |
| Accounts Receivable | $2.40 Million | 35.4% |
| Inventory | $-2.40 Million | -35.4% |
| Property, Plant & Equipment | $0.00 | 0.0% |
| Intangible Assets | $0.00 | 0.0% |
| Goodwill | $0.00 | 0.0% |
Asset Composition Trend (2016–2024)
This chart illustrates how Noxopharm Limited's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Noxopharm Limited's current assets represent 70.3% of total assets in 2024, a decrease from 94.9% in 2016.
- Cash Position: Cash and equivalents constituted 34.2% of total assets in 2024, down from 49.9% in 2016.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 0.0% of total assets, unchanged from 0.0% in 2016.
- Asset Diversification: The largest asset category is accounts receivable at 35.4% of total assets.
Noxopharm Limited Competitors by Total Assets
Key competitors of Noxopharm Limited based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
Halozyme Therapeutics Inc
NASDAQ:HALO
|
USA | $2.22 Billion |
|
Biomarin Pharmaceutical Inc
NASDAQ:BMRN
|
USA | $7.59 Billion |
|
ESSA Pharma Inc
NASDAQ:EPIX
|
USA | $110.50 Million |
|
Shenzhen CAU Technology Co Ltd
SHE:000004
|
China | CN¥260.55 Million |
|
Pacific Shuanglin Bio pharmacy Co Ltd
SHE:000403
|
China | CN¥9.58 Billion |
|
Nanhua Bio Medicine Co Ltd
SHE:000504
|
China | CN¥841.96 Million |
|
Jiangsu Sihuan Bioengineering Co Ltd
SHE:000518
|
China | CN¥509.14 Million |
|
Chengzhi Shareholding Co Ltd
SHE:000990
|
China | CN¥27.52 Billion |
Noxopharm Limited - Asset Efficiency Metrics
Asset efficiency metrics measure how effectively a company uses its assets to generate revenue and profits. These indicators help investors evaluate management's ability to deploy capital efficiently.
Asset Turnover Ratio
Measures how efficiently a company uses its assets to generate sales
Lower asset utilization - Noxopharm Limited generates 0.35x its asset value in annual revenue.
Return on Assets (ROA)
Measures how efficiently a company uses its assets to generate profits
Negative ROA - Noxopharm Limited is currently not profitable relative to its asset base.
Noxopharm Limited - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 3.83 | 9.52 | 0.49 |
| Quick Ratio | 5.75 | 9.52 | 0.38 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | $3.52 Million | $ 8.20 Million | $ -2.63 Million |
Noxopharm Limited - Advanced Valuation Insights
This section examines the relationship between Noxopharm Limited's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 3.04 |
| Latest Market Cap to Assets Ratio | 1.30 |
| Asset Growth Rate (YoY) | -33.0% |
| Total Assets | $6.78 Million |
| Market Capitalization | $8.80 Million USD |
Valuation Analysis
Above Book Valuation: The market values Noxopharm Limited's assets above their book value (1.30 x), reflecting positive investor sentiment about the company's future prospects.
Significant Asset Reduction: Noxopharm Limited's assets decreased by 33.0% over the past year, potentially indicating divestiture, restructuring, or challenging business conditions.
Annual Total Assets for Noxopharm Limited (2016–2024)
The table below shows the annual total assets of Noxopharm Limited from 2016 to 2024.
| Year | Total Assets | Change |
|---|---|---|
| 2024-06-30 | $6.78 Million | -33.02% |
| 2023-06-30 | $10.13 Million | -61.91% |
| 2022-06-30 | $26.59 Million | -44.43% |
| 2021-06-30 | $47.85 Million | +138.47% |
| 2020-06-30 | $20.07 Million | +366.63% |
| 2019-06-30 | $4.30 Million | -70.44% |
| 2018-06-30 | $14.55 Million | +414.37% |
| 2017-06-30 | $2.83 Million | +776.45% |
| 2016-06-30 | $322.73K | -- |